TrialCurveBEYOND: reconstructed Kaplan–Meier curves
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Clin Transl Oncol. 2022 Jun 27;24(11):2155–65. doi: 10.1007/s12094-022-02868-x |
|---|---|
| DOI | 10.1007/s12094-022-02868-x |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival at six months
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Group A not reached; Group B 4.0 months. Survival at 2 months: Group A 89%; Group B 69%. Hazard ratio Group A vs Group B 0.38 (95% CI 0.13–1.11).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Group A | 18 | 6 | not reached |
| Group B | 13 | 8 | 4.0 |
- Group A vs Group B: reconstructed HR 0.38 (95% CI 0.13–1.11)
Landmark survival (reconstructed)
| Time | Group A | Group B |
|---|---|---|
| 2 mo | 88.9% | 69.2% |
| 4 mo | 88.9% | 53.8% |
| 6 mo | 62.3% | 33.7% |
Checks against the published figure
- Group B median: printed 4, reconstructed 4 pass
- Group B events: printed 8, reconstructed 8 pass
- Group B n: printed 13, reconstructed 13 pass
- Group A events: printed 6, reconstructed 6 pass
- Group A n: printed 18, reconstructed 18 pass
- hazard ratio: printed 0.414, reconstructed 0.382 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/beyond-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/beyond-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Clin Transl Oncol. 2022 Jun 27;24(11):2155–65. doi: 10.1007/s12094-022-02868-x doi:10.1007/s12094-022-02868-x. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/beyond
Report a problem with these data
Related trials
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
- FOCUS4-D: Progression-free survival
- XELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: Overall survival; Progression-free survival
- BREAKWATER: Overall survival
- SCOT (primary analysis): Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials